Farmers & Merchants Trust Co of Chambersburg PA bought a new stake in Crispr Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 420 shares of the company’s stock, valued at approximately $26,000.

A number of other hedge funds also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Crispr Therapeutics by 13.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after acquiring an additional 343 shares during the last quarter. Traynor Capital Management Inc. lifted its stake in Crispr Therapeutics by 5.8% in the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after buying an additional 375 shares during the period. Commonwealth Equity Services LLC lifted its stake in Crispr Therapeutics by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after buying an additional 386 shares during the period. D. E. Shaw & Co. Inc. lifted its stake in Crispr Therapeutics by 7.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock valued at $331,000 after buying an additional 467 shares during the period. Finally, US Bancorp DE lifted its stake in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares during the period. Institutional investors and hedge funds own 49.83% of the company’s stock.

Several equities analysts have issued reports on the company. Goldman Sachs Group boosted their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. ValuEngine lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Roth Capital upped their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Finally, Canaccord Genuity upped their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research report on Wednesday, November 20th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $75.95.

Shares of NASDAQ:CRSP traded down $1.82 during trading on Friday, reaching $54.75. 1,224,856 shares of the stock were exchanged, compared to its average volume of 1,021,665. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of -119.02 and a beta of 3.20. The stock has a fifty day moving average of $63.18 and a two-hundred day moving average of $52.50. Crispr Therapeutics AG has a 1-year low of $29.34 and a 1-year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Sell-side analysts forecast that Crispr Therapeutics AG will post 0.65 EPS for the current year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at approximately $465,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 over the last three months. 21.40% of the stock is currently owned by insiders.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Guidelines for Successful Channel Trading

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link